Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Referanser til Hodgkin lymfom

Epidemiologi/patogenese/etiologi

Jaffe ES, Harris NL, Stein H and Vardiman JW. Tumours of Haematopoietic and lymphoid Tissue. Pathology and Genetics. WHO classification of tumours. IARC press. Lyon 2001.

Ekstrom-Smedby K. Epidemiology and etiology of non-Hodgkins lymphoma – a review. Acta Oncol 2006 45: 258-271

Cancer in Norway 2013, Cancer Registry of Norway, Institute of Population-based Research. Oslo, Norway 

Stadieinndeling

Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non- Hodgkinss lymphoma. J Clin Oncol 1999; 19: 1244?53.

Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkinss disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-6.

Overlevelse og prognostiske faktorer

Foss Abrahamsen A, Hannisdal E, Nome O et al. Clinical stage I and II Hodgkinss disease: Long-term results of therapy without laparatomy. Experience at one institution. Ann Oncol 1996; 7: 145-150.

Hasenclever D, Diehl V. A prognostic score for advanced Hodgkinss disease. International Prognostic Factors Project on Advanced Hodgkins?s Disease. N Engl J Med. 1998; 339: 1506-14.

Cancer in Norway 2015, Cancer Registry of Norway, Institute of Population-based Research. Oslo, Norway

The International non-Hodgkinss lymphoma prognostic factor project. A predictive model for aggressive non- Hodgkinss lymphoma N Engl J Med 1993; 329: 987-94.

Solal Séligny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-65.

Histologi, immunhistojemi og genetiske undersøkelser

Den norske patologforenings lymfomkode-utvalg: Forslag til Norsk SNOMED for lymfomer, oktober 2001.

Jaffe ES, Harris NL, Stein H and Vardiman JW. Tumours of Haematopoietic and lymphoid Tissue. Pathology and Genetics. WHO classification of tumours. IARC press. Lyon 2001.

Behandling av Hodgkins lymfom

Aleman BM, Raemaekers JM, Tirelli U, et al. (European Organization for Research and Treatment of Cancer Lymphoma Group). Involved-field radiotherapy for advanced Hodgkins's lymphoma. N Engl J Med. 2003 348:2396-406.

Diehl V, Franklin J, Hasenclever D et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkinss lymphoma: interim report from a trial of the German Hodgkinss Lymphoma Study Group. J Clin Oncol 1998; 16: 3810-21.

Foss Abrahamsen A, Hannisdal E, Nome O et al. Clinical stage I and II Hodgkinss disease: Long-term results of therapy without laparotomy. Experience at one institution. Ann Oncol 1996; 7: 145-150.

Foss Abrahamsen A, Hannisdal E, Nome O al. Prognostic variables and results of salvage treatment in Hodgkins?s disease. Ann Oncol 1996; 35: 67-72.

Foss Abrahamsen J, Andersen A, Nome O et al. Long- term risk of second malignancy after treatment of Hodgkinss disease: the influence of treatment, age and follow- up time. Ann Oncol 2002; 13(11): 1786-91.

Sankila R, Garwicz S, Olsen JH et al. Risk of subsequent malignant neoplasms among 1641 Hodgkinss disease patients diagnosed in childhood and adolescence: A population-based cohort study in the five Nordic countries. J Clin Oncol 1996; 14: 1442-6.

Schellog G. The balance between cure and late effects in childhood Hodgkinss lymphoma: The experience of the German-Austrian Study-Group since 1978. Ann Oncol 1996; 7 (Suppl 4): 67-72.

Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkins disease. N Engl J Med 2003; 348: 2386-95

Travis LB, Hill D, Dores GM et al. Cumulative absolute breast cancer risk for young women treated for Hodgkins’s lymphoma. J Natl Cancer Inst 2005; 97: 1428-37

Prosedyrer i Oncolex kan ikke erstatte faglig veiledning fra kvalifisert veileder. Den som følger prosedyrene har et selvstendig ansvar for at det foreligger nødvendig godkjenning, lisens eller autorisasjon.
Oslo universitetssykehus HF © 2019